Navigation Links
CyVek, Inc. Secures $5.5 Million in Series D Financing
Date:2/4/2013

WALLINGFORD, Conn., Feb. 4, 2013 /PRNewswire/ -- CyVek, Inc., an innovator in multi-analyte immunoassay technology, announced today that it has secured a Series D round of financing in the amount of $5.5 million.  Connecticut Innovations and a group of private investors participated in the round.

The Series D funding enables the company to create the infrastructure needed to commercialize its novel immunoassay technology, CyPlex™, an integrated test system which includes a proprietary microfluidic cartridge that allows the analysis of multiple biomarkers from very small amounts of biological samples.  This technology has broad appeal in research and clinical applications.  Initially the CyVek system will be used in biomarker analysis in life sciences, drug discovery and clinical research.  CyVek is currently in the beta testing phase.

Per Hellsund , CyVek founder, President and CEO, commented, "We are very pleased to have closed our Series D financing. The funding provided by our investors will enable us to complete development related activities and put together the team and infrastructure required to commercialize.  CyPlex™ continues to demonstrate excellent reproducibility coupled with unprecedented ease of use and will provide exceptional value to researchers and clinicians alike.  We have had extremely positive feedback from early customers and this validates our vision of CyVek fulfilling unmet needs in basic research, translational research and clinical diagnostics."

CyVek was formed in 2010 and is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led companies from start up to liquidity events.

About CyVek Inc.

CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays.  CyVek's  CyPlex™ is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings.  For more information about CyVek, please call 203-679-0395 or visit us on the web at www.cyvek.com

Contact:
Sheila Burns
203-679-0395


'/>"/>
SOURCE CyVek, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
2. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
3. Unisense FertiliTech A/S Secures 24 Million USD in New Capital Investment
4. Biomatrica Secures Financing of $5 Million
5. SurgiQuest, Inc. Secures Additional $18.5 Million Funding to Fuel Worldwide Expansion and Commercialization Efforts
6. Zafgen Secures $21 Million in Series D Financing
7. Flexion Therapeutics Secures $20 Million in Series B Financing
8. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. BioMotiv Secures $21 million in Initial Funding
11. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):